Literature DB >> 22093190

Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.

Thomas Rhodes1, Debra J Jacobson, Michaela E McGree, Jennifer L St Sauver, Aruna V Sarma, Cynthia J Girman, Michael M Lieber, George G Klee, Kitaw Demissie, Steven J Jacobsen.   

Abstract

PURPOSE: We describe cross-sectional associations of benign prostate specific antigen with clinical urological measures and examined the risk of future urological outcomes in 2 population based cohorts of black and white men, respectively.
MATERIALS AND METHODS: Two population based cohort studies were established to characterize the natural history of and risk factors for prostate disease progression in white and black male residents of Olmsted County, Minnesota, and Genesee County, Michigan, respectively.
RESULTS: The benign prostate specific antigen distribution was similar in black men at a median of 32.9 pg/ml (25th, 75th percentiles 17.3, 68.0) and white men at a median of 32.2 pg/ml (25th, 75th percentiles 16.6, 68.9, respectively). However, it was much lower than in previous reports. For Olmsted County men in the upper quartile of benign prostate specific antigen there was a fifteenfold increased risk of prostate cancer (HR 14.6, 95% CI 3.1-68.6) and a twofold higher risk of treatment for benign prostatic hyperplasia (HR 2.2, 95% CI 1.2-4.2) after adjusting for age. After additional adjustment for baseline prostate specific antigen the association between benign prostate specific antigen and prostate cancer risk was attenuated but remained almost ninefold higher for men in the upper quartile of benign prostate specific antigen (HR 8.7, 95% CI 1.8-42.4). The twofold higher risk of treatment for benign prostatic hyperplasia also remained after adjusting for baseline prostate specific antigen for men in the upper benign prostate specific antigen quartile (HR 1.9, 95% CI 0.9-4.0).
CONCLUSIONS: Results suggest that increased benign prostate specific antigen may help identify men with prostate cancer and those at risk for benign prostatic hyperplasia treatment.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093190      PMCID: PMC3307095          DOI: 10.1016/j.juro.2011.09.061

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  Determination of prostate volume by transrectal ultrasound.

Authors:  M K Terris; T A Stamey
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

2.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

3.  The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness.

Authors:  J T Wei; D Schottenfeld; K Cooper; J M Taylor; G J Faerber; M A Velarde; R Bree; J E Montie; K A Cooney
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

4.  The prevalence of prostatism: a population-based survey of urinary symptoms.

Authors:  C G Chute; L A Panser; C J Girman; J E Oesterling; H A Guess; S J Jacobsen; M M Lieber
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

Review 5.  Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men.

Authors:  K A Cooney; M S Strawderman; K J Wojno; K M Doerr; A Taylor; K H Alcser; S G Heeringa; J M Taylor; J T Wei; J E Montie; D Schottenfeld
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

6.  Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

Authors:  Eduardo I Canto; Herb Singh; Shahrokh F Shariat; Dolores J Lamb; Stephen D Mikolajczyk; Harry J Linton; Harry G Rittenhouse; Dov Kadmon; Brian J Miles; Kevin M Slawin
Journal:  Urology       Date:  2004-05       Impact factor: 2.649

7.  Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.

Authors:  Harry J Linton; Leonard S Marks; Lisa S Millar; Christine L Knott; Harry G Rittenhouse; Stephen D Mikolajczyk
Journal:  Clin Chem       Date:  2003-02       Impact factor: 8.327

8.  Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time.

Authors:  S J Jacobsen; G G Klee; H Lilja; G L Wright; J E Oesterling
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

9.  A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men.

Authors:  S J Jacobsen; H A Guess; L Panser; C J Girman; C G Chute; J E Oesterling; M M Lieber
Journal:  Arch Fam Med       Date:  1993-07

10.  Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study.

Authors:  Aruna V Sarma; John T Wei; Debra J Jacobson; Rodney L Dunn; Rosebud O Roberts; Cynthia J Girman; Michael M Lieber; Kathleen A Cooney; David Schottenfeld; James E Montie; Steven J Jacobsen
Journal:  Urology       Date:  2003-06       Impact factor: 2.649

View more
  2 in total

1.  Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.

Authors:  Thomas Rhodes; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; Cynthia J Girman; Michael M Lieber; George G Klee; Kitaw Demissie; Steven J Jacobsen
Journal:  Urology       Date:  2012-03       Impact factor: 2.649

Review 2.  Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

Authors:  Todd Morgan; Ganesh Palapattu; John Wei
Journal:  Curr Urol Rep       Date:  2015-09       Impact factor: 3.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.